Volume 14, Issue 3 (Atumn 2017)                   Sci J Iran Blood Transfus Organ 2017, 14(3): 195-203 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shamsian B, Zavar N, Ahmadi Khatiri F, Arzanian M, Shamshiri A, Kazemian M. Results of the two types of treatment "Rituxmab and Splenectomy" in children with chronic ITP, Mofid Children's Hospital . Sci J Iran Blood Transfus Organ 2017; 14 (3) :195-203
URL: http://bloodjournal.ir/article-1-1047-en.html
Results of the two types of treatment "Rituxmab and Splenectomy" in children with chronic ITP, Mofid Children's Hospital
B.Sh. Shamsian , N. Zavar * , F. Ahmadi Khatiri , M.T. Arzanian , A.R. Shamshiri , M. Kazemian
Keywords: Key words: Immune Thrombocytopenic Purpura, Rituximab, Splenectomy
Full-Text [PDF 353 kb]   (7110 Downloads)     |   Abstract (HTML)  (6062 Views)
Full-Text:   (28132 Views)
    References:
 
  1. Journeycake JM. Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics. Hematology Am Soc Hematol Educ Program 2012; 2012: 444-9.
  2. Warrier R, Chauhan A. Management of Immune Thrombocytopenic Purpura: An Update. Ochsner J 2012; 12(3): 221-7.
  3. Belletrutti M, Ali K, Barnard D, Blanchette V, Chan A, David M, et al. Chronic immune thrombocytopenic purpura in children: a survey of the canadian experience. J Pediatr Hematol Oncol 2007; 29(2): 95-100.
  4. Alavi S, Malek F, Eghbali A, Arzanian MT, Shamsian Sh, Azargashb E. Immune Thrombocytopenic Purpura and relevant factors in patients in Mofid Children Hospital from 2003 to 2008. Sci J Iran Blood Transfus Organ 2009; 6(3): 165-73. [Article in Farsi]
  5. George JN. Definition, diagnosis and treatment of immune thrombocytopenic purpura. Haematologica 2009; 94(6): 759-62.
  6. Lusher JM, Iyer R. Idiopathic thrombocytopenic purpura in children. Semin Thromb Hemost 1977; 3(3): 175-99.
  7. Orkin SH, Nathan DG, Ginsburg D, Thomas Look A, Fisher DE, Lux S. Nathan and Oski’s Hematology and Oncology  of   Infancy and Childhood. 8thed. Philadelphia: Saunders; 2015. p.1079-87.
  8. Medeiros D, Buchanan GR. Current controversies in the management of idiopathic thrombocytopenic purpura during childhood. Pediatr Clin North Am 1996; 43(3): 757-72.
  9. McCrae K. Immune thrombocytopenia: no longer ‘idiopathic’. Cleve Clin J Med 2011; 78(6): 358-73.
  10. Ansari Sh, Rostami T, Yousefian S, Kiumarsi A, Miri-Aliabad G, Ramim T. Rituximab efficacy in the treatment of children with chronic immune thrombocytopenic purpura. Pediatr Hematol Oncol 2014; 31(6): 555-62.
  11. Chohana F, Gianga J, Boekhorstb P. Efficacy and safety of rituximab, splenectomy and dexamethasone in patients with Idiopathic thrombocytopenic purpura (ITP). Erasmus Journal of Medicine 2013; 3(2): 14-7.
  12. Aladjidi N, Santiago R, Pondarré C, Lambilliotte A, Leverger G, Sebillotte CG, et al. Revisiting Splenectomy in Childhood Immune Thrombocytopenic Purpura in the Era of New Therapies: The French Experience. J Blood Disord Transf 2012; S3: 003.
  13. Chong BH. Diagnosis, treatment and pathophysiology of autoimmune thrombocytopenias. Crit Rev Oncol Hematol 1995; 20(3): 271-96.
  14. Patel VL, Mahévas M, Lee S, Stasi R, Cunningham-Rundles S, Godeau B, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012; 119(25): 5989-95.
  15. Lanzkowsky P. Manual of Pediatric Hematology and Oncology. 5th ed. Burlington: Elsevier; 2011. p. 343-53.
  16. Platelet Disorder Support Association. Ohio: B-cell Depletion (anti-CD20); 2016. Available from: https://www.pdsa.org/treatments/conventional/b-cell-depletion.html.
  17.  Journeycake  JM. Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics. Hematology Am Soc Hematol  Educ  Program  2012;
2012: 444-9.
  1. Liang Y, Zhang L, Gao J, Hu D, Ai Y. Rituximab for Children with Immune Thrombocytopenia: A Systematic Review. PLoS One 2012; 7(5): e36698.
  2. Ramenghi U, Amendola G, Farinasso L,  Giordano P, Loffredo G, Nobili B, et al. Splenectomy in children with chronic ITP: Long-term efficacy and relation between its outcome and responses to previous treatments. Pediatr Blood Cancer 2006; 47(5 Suppl): 742-5.
  3. Donato H, Picón A, Rapetti MC, Rosso A, Schvartzman G, Drozdowski C, et al. Splenectomy and spontaneous remission in children with chronic idiopathic thrombocytopenic purpura. Pediatr Blood Cancer 2006; 47(5 Suppl): 737-9.
 
 
 


 
 
 
 
Sci J Iran Blood Transfus Organ 2017; 14(3): 195-203
Original Article
 

 

Results of the two types of treatment "Rituxmab  and Splenectomy" in   children with  chronic ITP, Mofid
Children's Hospital
 
Shamsian B.Sh.1, Zavar N.1, Ahmadi Khatiri F.1, Arzanian M.T.1,
 Shamshiri A.R.1, Kazemian M.1
 
1Mofid Children's Hospital, Pediatric Congenital Hematologic Disorders Research Center, Tehran, Iran
 
 
Abstract
Background and Objectives
In this study, the treatment results of "Rituximab therapy and Splenectomy" in chronic patients of ITP were collected in Mofid Children's Hospital during the years of 1380-1391.
 
Materials and Methods
In this descriptive study, the charts of patients with chronic ITP in years of 1380-1391 were studied. Variables including sex, age at rituximab therapy spelenectomy, treatment response, side effects, prespelenectomy vaccination and prophylactic antibiotics were assessed. The data were analyzed by EXCEL & SPSS 11.5.
 
Results
Chronic ITP patients were 39 cases, 18 males and 21 females; 17 (43.5%) patients received rituximab with 375 mg/mm2 and 100 mg/mm2, between 1-9 times. Three patients  of the first group completely responded (plt > 100000/mm3). Complications, fever and pancytopenia  were seen in 2 patients. The first patient with fever responded to the supportive  treatment. The other patient showed severe pancytopenia after receiving the second dose of Rituximab but at last recovered after 7 months with the supportive therapy.  Six out of 39 (15%) patients of chronic ITP  with the history of variable treatments had been splenectomised and 4(66%) patients had completely responded. Five out of 6 (85%) patients  received  complete  vaccination before splenectomy. No sepsis or thrombosis was seen.
 
Conclusions 
Probably the low number of spelenectomised patients is the result of oral treatment success in prevention of spelenectomising and splenectomy could be replaced by rituximab therapy if accessible. On the other hand, because of the low number of cases, it was statistically impossible to compare the results of the two groups.
 
Key words: Immune Thrombocytopenic Purpura, Rituximab, Splenectomy
 
 
 
 
 
 
 
Received:  20 Jun  2016
Accepted: 20 May 2017
 
 

Correspondence: Zavar N., MD. Mofid Children's Hospital, Pediatric Congenital Hematologic Disorders Research Center.
Postal Code: 1546815514, Tehran, Iran. Tel: (+9821) 22227020; Fax: (+9821) 22220254
E-mail: nnavidzzavar@yahoo.com
Type of Study: Historical Rreview | Subject: Hematology
Published: 2017/09/11
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Scientific Journal of Iran Blood Transfus Organ

Designed & Developed by : Yektaweb